BR0215260A - Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro - Google Patents

Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro

Info

Publication number
BR0215260A
BR0215260A BR0215260-6A BR0215260A BR0215260A BR 0215260 A BR0215260 A BR 0215260A BR 0215260 A BR0215260 A BR 0215260A BR 0215260 A BR0215260 A BR 0215260A
Authority
BR
Brazil
Prior art keywords
protease inhibitors
broad spectrum
hiv protease
het
hydroxy
Prior art date
Application number
BR0215260-6A
Other languages
English (en)
Inventor
Sandrine Marie Hele Vendeville
Wim Gaston Verschueren
Abdellah Tahri
Samuel Leo Christiaan Moors
Montserrat Erra Sola
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BR0215260A publication Critical patent/BR0215260A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"INIBIDORES DE HIV PROTEASE DE SULFONAMIDA CONTENDO FENILA SUBSTITUìDA HETEROCìCLICA DE AMPLO ESPECTRO". A presente invenção refere-se a compostos tendo a fórmula (I), N-óxidos, sais, formas estereoisoméricas, misturas racêmicas, pró-drogas, ésteres e seus metabólitos, em que Harila é heterociclo monocíclico, bicíclico ou tricíclico aromático tendo de 3 a 14 membros de anel que contém um ou mais membros de anel heteroátomo selecionados de nitrogênio, oxigênio e enxofre e que podem opcionalmente estar substituídos sobre (i) um ou mais átomos de carbono por C~ 1-6~ alquila, halogênio, hidróxi, amino opcionalmente mono-ou dissubstituído, nitro, ciano, haloC~ 1-6~,-6 alquila, carboxila, C~ 3-7~ cicloalquila, aminocarbonila opcionalmente mono-ou dissubstituída, metiltio, metilsulfonila, arila, -(R~ 7 a~)n-M-~ 7b~, Het^ 1^ e Het^ 2^; pelo que os substituintes opcionais sobre qualquer função de amino são independentemente selecionados de R~ 5~ e -A-R~ 6~; e sobre (II) um átomo de nitrogênio se presente por hidróxi ou -A-R~ 6~. Este ulteriormente refere-se ao seu uso como inibidores de protease HIV de amplo espectro, a processos para a sua preparação bem como a composições farmacêuticas e a kits compreendendo as mesmas. Ela também refere-se a suas combinações com um outro agente anti-retroviral, e ao seu uso em ensaios como compostos de referência ou como reagentes.
BR0215260-6A 2001-12-21 2002-12-20 Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro BR0215260A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01205115 2001-12-21
PCT/EP2002/014839 WO2003053435A1 (en) 2001-12-21 2002-12-20 Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors

Publications (1)

Publication Number Publication Date
BR0215260A true BR0215260A (pt) 2004-12-07

Family

ID=8181520

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215260-6A BR0215260A (pt) 2001-12-21 2002-12-20 Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro

Country Status (24)

Country Link
US (1) US7763641B2 (pt)
EP (1) EP1463502B1 (pt)
JP (1) JP4578101B2 (pt)
KR (1) KR100942743B1 (pt)
CN (1) CN100448444C (pt)
AP (1) AP1922A (pt)
AR (1) AR037976A1 (pt)
AT (1) ATE516029T1 (pt)
AU (1) AU2002361235B2 (pt)
BR (1) BR0215260A (pt)
CA (1) CA2470964C (pt)
EA (1) EA009556B1 (pt)
HK (1) HK1070001A1 (pt)
HR (1) HRP20040662B1 (pt)
HU (1) HUP0500164A3 (pt)
IL (2) IL162574A0 (pt)
MX (1) MXPA04006201A (pt)
MY (1) MY138657A (pt)
NO (1) NO328122B1 (pt)
NZ (1) NZ533665A (pt)
PL (1) PL216539B1 (pt)
TW (1) TWI336621B (pt)
WO (1) WO2003053435A1 (pt)
ZA (1) ZA200405784B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516250A (ja) * 2002-12-18 2006-06-29 サイトビア インコーポレイティッド カスパーゼ活性化剤およびアポトーシス誘導物質としての３，５−二置換−［１，２，４］−オキサジアゾールおよびそれらの誘導体ならびにそれらの使用
WO2005030194A1 (en) * 2003-09-30 2005-04-07 Tibotec Pharmaceuticals Ltd. Hcv inhibitiing sulfonamides
EP2422780A1 (en) * 2004-05-07 2012-02-29 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
JP5260965B2 (ja) 2005-02-25 2013-08-14 テイボテク・フアーマシユーチカルズ プロテアーゼ阻害剤前駆体合成
WO2008004100A2 (en) 2006-07-05 2008-01-10 Pfizer Products Inc. Therapeutic compounds
US20120316161A1 (en) 2009-12-23 2012-12-13 Katholieke Universiteit Leuven Novel antiviral compounds
JP6006211B2 (ja) * 2010-09-02 2016-10-12 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ３員環の縮合エーテルカルバメートおよびその使用
EP2640729B1 (en) 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibitors of hiv replication
AU2011331301A1 (en) 2010-11-15 2013-05-23 Katholieke Universiteit Leuven Antiviral condensed heterocyclic compounds
JPWO2016039403A1 (ja) * 2014-09-11 2017-06-29 塩野義製薬株式会社 持続性ｈｉｖプロテアーゼ阻害剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1995006030A1 (en) 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
BR9407686A (pt) 1993-10-01 1997-02-04 Astra Ab Processo e aparelho para o tratamento de um medicamento em pó finamente dividido uso do aparelho e aglomerados
EP1586558A3 (en) 1995-01-20 2005-10-26 G.D. Searle LLC. Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors
US5756533A (en) 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
PL184771B1 (pl) 1995-03-10 2002-12-31 Searle & Co Związek stanowiący hydroksyetyloaminosulfonamid pirolidynokarbonyloaminokwasu, kompozycja zawierająca ten związek, jego zastosowanie do wytwarzania kompozycji do leczenia infekcji retrowirusowej i sposób zapobiegania replikacji retrowirusa in vitro
US5705500A (en) 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
JPH09124630A (ja) * 1995-10-26 1997-05-13 Kissei Pharmaceut Co Ltd カルバミン酸テトラヒドロフリルエステル誘導体の製造方法
EP0861249A1 (en) 1995-11-15 1998-09-02 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
ATE255883T1 (de) 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
HU224217B1 (hu) 1997-03-26 2005-06-28 Janssen Pharmaceutica N.V. Gombaellenes hatóanyaggal és polimerrel bevont magrészt tartalmazó pelletek
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
JP2001527062A (ja) 1997-12-24 2001-12-25 バーテックス ファーマシューティカルズ インコーポレイテッド アスパルチルプロテアーゼインヒビターのプロドラッグ
CA2335477C (en) * 1998-06-19 2010-11-30 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of aspartyl protease
EP1088098B2 (en) 1998-06-23 2015-07-01 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Fitness assay and methods for reducing resistance of hiv to therapy
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods

Also Published As

Publication number Publication date
WO2003053435A1 (en) 2003-07-03
EP1463502A1 (en) 2004-10-06
PL370801A1 (en) 2005-05-30
IL162574A0 (en) 2005-11-20
CN100448444C (zh) 2009-01-07
TWI336621B (en) 2011-02-01
ATE516029T1 (de) 2011-07-15
HRP20040662B1 (hr) 2013-12-06
TW200410673A (en) 2004-07-01
ZA200405784B (en) 2005-11-30
EP1463502B1 (en) 2011-07-13
KR20040077863A (ko) 2004-09-07
CA2470964A1 (en) 2003-07-03
AR037976A1 (es) 2004-12-22
NO328122B1 (no) 2009-12-14
EA009556B1 (ru) 2008-02-28
US7763641B2 (en) 2010-07-27
HK1070001A1 (en) 2005-06-10
JP4578101B2 (ja) 2010-11-10
KR100942743B1 (ko) 2010-02-16
US20050222215A1 (en) 2005-10-06
AP2004003083A0 (en) 2004-09-30
PL216539B1 (pl) 2014-04-30
EA200400828A1 (ru) 2005-02-24
IL162574A (en) 2014-09-30
CN1620292A (zh) 2005-05-25
NO20043114L (no) 2004-09-20
MY138657A (en) 2009-07-31
NZ533665A (en) 2005-10-28
JP2005513102A (ja) 2005-05-12
HUP0500164A3 (en) 2009-03-30
MXPA04006201A (es) 2004-12-06
HUP0500164A2 (hu) 2005-05-30
CA2470964C (en) 2013-07-02
AP1922A (en) 2008-11-21
AU2002361235B2 (en) 2008-07-24
AU2002361235A1 (en) 2003-07-09
HRP20040662A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
AR059778A1 (es) Compuestos de pirrolotriazina inhibidores de quinasas p38,composiciones farmaceuticas que los contienen y usos en gran variedad de procesos inflamatorios.
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
BR0215260A (pt) Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro
AR065901A1 (es) Derivados de pirrolipirimidina
CO5550398A2 (es) 7-aminotriazolpirimidinas, proceso e intermedios para su preparacion, composiciones que las comprenden y su uso para controlar hongos dañinos
AR088921A2 (es) PROCESO PARA LA PREPARACION DE DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTA mGluR5, COMPOSICIONES Y USO DE LOS COMPUESTOS
CY1112006T1 (el) Μακροκυκλικοι αναστολεις του ιου της ηπατιτιδας c
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
AR039665A1 (es) Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa
PE20221901A1 (es) Un compuesto aromatico sustituido con anillo fundido, metodo de preparacion, composicion herbicida y su uso
UY28149A1 (es) Compuestos quimicos
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
CO5611110A2 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion, composiciones farmaceuticas y usos de los mismos
AR078875A2 (es) Compuesto uracilo composicion herbicida que lo comprende, metodo para controlar malezas con el mismo, su uso.
AR057705A1 (es) 3-acilaminobenzanilidas insecticidas
ES2546502T3 (es) 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
CO6220878A2 (es) Composicion herbicida que comprende un derivado de isoxazolina o una sal del mismo
AR065867A1 (es) Compuestosde isoxazolina y su uso en el control de plagas
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
DK0682659T3 (da) 4-Benzoylisoxazolderivater, deres fremstilling samt deres anvendelse som herbicider
AR054369A1 (es) Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CO5700716A2 (es) Imidazolo-5-il-2-anilinopirimidinas como agentes para la inhibicion de la proliferacion celular
BR0208309A (pt) Derivados de arilisoxazolina, processos para a sua preparação e sua aplicação como composições praguicidas

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: TIBOTEC PHARMACEUTICALS LTD. (IE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070001806/RJ DE 05/01/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/4178, 31/18; C07D 231/12, 277/42, 263/32, 513/04, 233/54, 233/88, 493/04, 277/40, 417/14, 417/12; A61K 31/506, 31/427, 31/425; A61P 31/18

Ipc: A61K 31/4178 (2011.01), A61K 31/18 (2011.01), C07D

B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/4178, 461K 31/18, C07D 231/12, C07D 277/42, C07D 263/32, C07D 513/04, C07D 233/54, C07D 233/88, C07D 493/04, C07D 277/40, C07D 417/14, A61P 31/12, A61P 43/00

Ipc: A61K 31/4178 (2006.01), A61K 31/18 (2006.01), C07D

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]